Innovative Platform Radiant Genomics has developed a cutting-edge synthetic biology platform that enables scalable production of natural organism chemistry, presenting opportunities for collaborations in industries such as agriculture, pharmaceuticals, and specialty chemicals looking for advanced biotechnological solutions.

Recent Acquisition Since being acquired by Zymergen in early 2018, Radiant Genomics benefits from increased resources and technological integration, which can facilitate strategic partnerships and co-development projects in molecular engineering and biomanufacturing sectors.

Market Potential Target end-markets including agriculture, pharma, and specialty chemicals indicate multiple industry verticals that may require custom biotech solutions, offering multiple avenues for selling tailored research and development services or products.

Growth Opportunity With a small team of 11-50 employees and a revenue below one million dollars, Radiant Genomics is positioned for growth, making it a potential partner or customer for companies providing biosciences infrastructure, funding, or technology adoption services.

Tech Stack & Digital Presence Utilizing widely adopted web and analytics tools like WordPress, Google Fonts, and Google Analytics suggests an active online presence and potential for digital collaborations or outreach, aiding in direct sales and educational campaigns.